Is it possible to halve the incidence of liver cancer in China by 2050?

Ju-Fang Shi1, Maomao Cao1, Yuting Wang2

  • 1Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Insights

Liver cancer, often caused by hepatitis B and C (HBV/HCV) infections, is declining in China. With scaled-up vaccination and prevention, global liver cancer control is achievable.

Area of Science:

  • Hepatology
  • Oncology
  • Public Health

Background:

  • Chronic hepatitis B and C (HBV/HCV) infections are major causes of liver cancer globally.
  • Liver cancer control is a significant global health challenge, with varying incidence rates across countries.
  • China's historical contribution to the global liver cancer burden is substantial, though recent declines are observed.

Purpose of the Study:

  • To review the liver cancer burden and risk factors in China compared to other nations.
  • To assess the implementation and outcomes of liver cancer prevention interventions over three decades.
  • To predict future liver cancer incidence trends in China and identify research needs and policy recommendations.

Main Methods:

  • Bayesian age-period-cohort analysis to examine recent liver cancer trends in China.
  • Literature survey to identify current research gaps and relevant national policies.
  • Review of primary and secondary prevention intervention implementation and outcomes.

Main Results:

  • Liver cancer incidence in China has shown a recent national decline.
  • Projections indicate a potential halving of liver cancer incidence in China by 2050.
  • Significant progress in implementing prevention interventions has been achieved over the past 30 years.

Conclusions:

  • Global liver cancer control is feasible with widespread vaccination and scaled-up interventions.
  • Targeted strategies and policies are crucial for achieving long-term liver cancer elimination.
  • Continued research and policy refinement are necessary to address remaining challenges in liver cancer control.